Laboratory and clinical study of balofloxacin, a new fluoloquinolone, in urinary tract infection

Keizo Suzuki, Masaki Horiba, Kiyohito Ishikawa, Shinobu Katoh, Yorio Naide, Kiyotaka Hoshinaga, Masanori Yanaoka, Toshiyuki Tanaka, Norihiko Okishio

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Balofloxacin (BLFX), one of the newer quinolones, was investigated for its in vitro activity, diffusion into prostatic fluid (PF) and clinical efficacy in the treatment of urinary tract infection (UTI). The results obtained were as follows. 1. In vitro activity: Against 80 strains of Enterococcus faecalis isolated from UTI, the MIC of BLFX ranged from 0.20˜25 μg/ml, and the MIC50and MIC90 were 0.78 μg/ml and 12.5 ƒÊg/ml, respectively, roughly comparable to sparfloxacin. The drug appeared to be superior to other reference drugs such as norfloxacin, ofloxacin and ciprofloxacin. However, BLFX was less potent against 50 strains of Pseudomonas aeruginosa, for which the MIC50 and MIC90 were as much as 25 μg/ml and > 100 μg/ml.

Original languageEnglish
Pages (from-to)310-316
Number of pages7
JournalJapanese Journal of Chemotherapy
Volume43
DOIs
Publication statusPublished - 01-01-1995
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Laboratory and clinical study of balofloxacin, a new fluoloquinolone, in urinary tract infection'. Together they form a unique fingerprint.

  • Cite this

    Suzuki, K., Horiba, M., Ishikawa, K., Katoh, S., Naide, Y., Hoshinaga, K., Yanaoka, M., Tanaka, T., & Okishio, N. (1995). Laboratory and clinical study of balofloxacin, a new fluoloquinolone, in urinary tract infection. Japanese Journal of Chemotherapy, 43, 310-316. https://doi.org/10.11250/chemotherapy1995.43.Supplement5_310